雷卡西马布作为非家族性高胆固醇血症的他类药物补充疗法:随机的第三期REMAIN-2试验
Yihong Sun1, Qiang Lv1, Yuhan Guo2
1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Journal of the American College of Cardiology
|November 6, 2024
概括
在非家族性高胆固醇血症患者中,recaticimab在加入他类药物时显著降低了LDL-C. 这种新疗法可有效降低脂质,每隔12周服用一次,改善治疗选择.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 目前的蛋白转化酶子素/素9型 (PCSK9) 抑制剂需要频繁的剂量.
- 雷卡西奇马布是一种新型单克隆抗体,向PCSK9.
- 第1b/2期试验显示,雷卡西马布在降低低频率较低的剂量下降LDL-C的疗效.
研究的目的:
- 评估雷卡西马布作为他类药物补充治疗的48周疗效和安全性.
- 评估非家族性高胆固醇血症患者的雷卡西马布.
- 为了确定recaticimab的最佳剂量方案.
主要方法:
- 这是一项多中心,随机,双盲,安慰剂控制的第三期试验 (REMAIN-2).
- 患者接受了稳定的他类药物治疗 +/- 埃泽米布/芬酸盐.
- 随机选择使用雷卡西马布 (150mg Q4W,300mg Q8W,450mg Q12W) 或安慰剂,持续48周.
主要成果:
- 与安慰剂相比,雷卡西马布在24周显著降低了LDL-C水平 (P < 0.0001).
- 在所有雷卡西马布剂量中,LDL-C降低一直持续到第48周.
- 与治疗相关的不良事件在雷卡西马布和安慰剂组中同样低.
结论:
- 雷卡西马布在补充他类药物治疗时显示出显著且持续的LDL-C降低.
- 它为非家族性高胆固醇血症提供了一种新的治疗选择,剂量间隔延长至12周.
- 这些发现支持recaticimab在管理高胆固醇血症方面的潜力.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
551
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
551
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
3
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
3
01:21Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
01:14Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
7
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
7
01:25Antihypertensive Drugs: Direct Renin Inhibitors
498
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
498